Comparison of transcatheter arterial chemoembolization, laparoscopic radiofrequency ablation, and conservative treatment for decompensated cirrhotic patients with hepatocellular carcinoma

被引:28
作者
Hsieh, Chung-Bao [1 ]
Chang, Hao-Ming [1 ]
Chen, Teng-Wei [1 ]
Chen, Chung-Jueng [1 ]
Chan, De-Chuan [1 ]
Yu, Jyh-Cherng [1 ]
Liu, Yao-Chi [1 ]
Chang, Tzu-Ming [2 ]
Shen, Kuo-Liang [1 ]
机构
[1] Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Med, Devis Gen Surg,Dept Surg, Taipei, Taiwan
[2] Tungs Taichung Metroharbor Hosp, Dept Surg, Taichung, Taiwan
关键词
D O I
10.3748/wjg.v10.i4.505
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To compare the therapeutic effect of transcatheter arterial chemoembolization (TACE), laparoscopic radiofrequency ablation (LRFA), and conservative treatment for the therapy of decompensated liver cirrhosis patients with hepatocellular carcinomas (HCC). METHODS: Between October 2000 and July 2003, one hundred patients with histologically proven primary HCC and clinical decompensated liver cirrhosis (Child classification B or C) were included in this study. Forty patients received LRFA (LRFA group), twenty received TACE (TACE group), and forty received conservative treatment (control group). We compared the survival, recurrence, and complication rates in these three groups, making adjustment using the tumor metastastic node staging system. RESULTS: The major complication rate in the TACE group (9/20) was significantly higher than that in the LRFA group (7/40). For patients with TMN stage II HCC, the survival rate of the LRFA group was better than that of the TACE and control groups (P=0.003) but the recurrence rates befween the LRFA and TACE groups did not differ. CONCLUSION: The LRFA group of patients had better clinical outcomes in terms of survival and complication rates in comparison with the TACE group or conservative treatment in patients with decompensated liver cirrhosis, especially in TMN patients with stage II HCC. LRFA is thus an appropriate alternative treatment for poor liver function among patients with HCC.
引用
收藏
页码:505 / 508
页数:4
相关论文
共 24 条
[1]   Nonsurgical treatment of hepatocellular carcinoma [J].
Aguayo, A ;
Patt, YZ .
SEMINARS IN ONCOLOGY, 2001, 28 (05) :503-513
[2]  
American Joint Committee on Cancer, 2002, AJCC CANC STAGING MA, P3
[3]  
American Liver Tumor Study Group, 1998, RAND PROSP MULT TRIA
[4]  
Bloomston M, 2002, AM SURGEON, V68, P827
[5]   Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors [J].
Bowles, BJ ;
Machi, J ;
Limm, WML ;
Severino, R ;
Oishi, AJ ;
Furumoto, NL ;
Wong, LL ;
Oishi, RH .
ARCHIVES OF SURGERY, 2001, 136 (08) :864-868
[6]  
Caridi J, RADIOFREQUENCT ABLAT
[7]   A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma [J].
Chan, AO ;
Yuen, MF ;
Hui, CK ;
Tso, WK ;
Lai, CL .
CANCER, 2002, 94 (06) :1747-1752
[8]   Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis [J].
Curley, SA ;
Izzo, F ;
Ellis, LM ;
Vauthey, JN ;
Vallone, P .
ANNALS OF SURGERY, 2000, 232 (03) :381-389
[9]  
Cuschieri A, 1999, ENDOSCOPY, V31, P318
[10]   PERCUTANEOUS ABLATION THERAPY FOR HEPATOCELLULAR CARCINOMAS [J].
DAGOSTINO, HB ;
SOLINAS, A .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1995, 164 (05) :1165-1167